Products
Crexavibart Biosimilar Monoclonal Antibody (SARS-CoV-2 Spike RBD) for Research
Cat No.: GMP-Bios-INN-1145
Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Crexavibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Crexavibart (development code C-144-LS) is a monoclonal antibody targeting the SARS-CoV-2 spike protein. It is developed by NIAID for COVID-19. It is in Phase II/III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1145-1mg | 1mg | 3090 |
| GMP-Bios-INN-1145-10mg | 10mg | |
| GMP-Bios-INN-1145-100mg | 100mg | |
| GMP-Bios-INN-1145-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Crexavibart biosimilar, Whole mAb: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
| INN Name | Crexavibart |
| Target | SARS-CoV-2 Spike RBD |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 7k90:HL:MN:OP/8dce:HH |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | NIAID |
| Conditions Approved | na |
| Conditions Active | COVID-19 |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
